Metformin and Type 2 Diabetes Prevention
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
IN BRIEF Metformin, an established therapy for the treatment of type 2 diabetes, has demonstrated safety and effectiveness in the prevention or delay of type 2 diabetes in people at high risk. The Diabetes Prevention Program randomized clinical trial demonstrated that intensive lifestyle intervention and metformin therapy reduced progression to diabetes by 58 and 31%, respectively, compared to placebo in people at risk of type 2 diabetes. Although lifestyle intervention was beneficial in all groups, metformin had a selectively greater effect in those who were more obese, had a higher fasting glucose, had a history of gestational diabetes, or were younger. Long-term effects included an 18% diabetes reduction with metformin compared to placebo over 15 years, a reduction in microvascular complications among those who did not progress to diabetes (without difference among treatment arms), and suggestion by coronary calcium assessment of a possible impact on atherosclerosis in men. Although long-term follow-up to assess later-stage outcomes is underway, current efforts to address gaps in evidence and translation remain of significant public health interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“metformin was no more effective than the control condition in older adults.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“Notably, those older than 60 years showed the best response, with a 71% reduction in incident diabetes during this timeframe.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“By contrast, metformin was no more effective than the control condition in older adults.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“In the DPP, participants randomly assigned to an intensive lifestyle intervention including diet and exercise reduced their risk of incident T2D by 58% at three years compared to the control group (lifestyle advice only), and this intervention was significantly better than metformin prescription [386].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“In the DPP, participants randomly assigned to an intensive lifestyle intervention including diet and exercise reduced their risk of incident T2D by 58% at three years compared to the control group (lifestyle advice only), and this intervention was significantly better than metformin prescription [386].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“Although no significant differences in blood pressure or lipids were seen compared to placebo during the DPP (15), metformin improved lipoprotein subfractions (16), C-reactive protein (CRP) (17), and tissue plasminogen activator (tPA) (17) and reduced the incidence of metabolic syndrome by 17% (18).”
BackgroundSelf-citationRatner, R. E., Christophi, C. A., Metzger, B. E., Dabelea, D., Bennett, P. H., Pi-Sunyer, X., Fowler, S., Kahn, S. E., & The Diabetes Prevention Program Research Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0772 · Cited by 867
Self-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572 · cited 1×
“Although no significant differences in blood pressure or lipids were seen compared to placebo during the DPP (15), metformin improved lipoprotein subfractions (16), C-reactive protein (CRP) (17), and tissue plasminogen activator (tPA) (17) and reduced the incidence of metabolic syndrome by 17% (18).”
BackgroundLong-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3754 · Cited by 536
Self-citationThe Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes
Paulweber, B., Valensi, P., Lindström, J., Lalic, N., Greaves, C., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., et al. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0029-1240928 · Cited by 469
Aroda, V. R., Christophi, C. A., Edelstein, S. L., Zhang, P., Herman, W. H., Barrett-Connor, E., Delahanty, L. M., Montez, M. G., Ackermann, R. T., Zhuo, X., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3761 · Cited by 467
Self-citationThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
The Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.4.977 · Cited by 218
for the Diabetes Prevention Program Research Group, Aroda, V. R., Knowler, W. C., Crandall, J. P., Perreault, L., Edelstein, S. L., Jeffries, S. L., Molitch, M. E., Pi-Sunyer, X., Darwin, C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4361-9 · Cited by 194
Self-citationDungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s005 · Cited by 157
Diabetes Prevention Program Research Group (2015) · Diabetes Care · doi:10.2337/dc14-0886 · Cited by 139
Goldberg, R. B., Aroda, V. R., Bluemke, D. A., Barrett-Connor, E., Budoff, M., Crandall, J. P., Dabelea, D., Horton, E. S., Mather, K. J., Orchard, T. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025483 · Cited by 137
Self-citationLachin, J. M., Christophi, C. A., Edelstein, S. L., Ehrmann, D. A., Hamman, R. F., Kahn, S. E., Knowler, W. C., Nathan, D. M., & on behalf of the DPP Research Group (2007) · Diabetes · doi:10.2337/db06-0918 · Cited by 107
Moin, T., Li, J., Duru, O. K., Ettner, S., Turk, N., Keckhafer, A., Ho, S., & Mangione, C. M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1773 · Cited by 90
Goldberg, R., Temprosa, M., Otvos, J., Brunzell, J., Marcovina, S., Mather, K., Arakaki, R., Watson, K., Horton, E., & Barrett-Connor, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1452 · Cited by 74
Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
Tseng, E., Yeh, H.-C., & Maruthur, N. M. (2017) · Diabetes Care · doi:10.2337/dc16-1509 · Cited by 72 · cited 1×
“7% (27), and in a national sample of insured adults, only 3.”
BackgroundGoldberg, R. B., Temprosa, M. G., Mather, K. J., Orchard, T. J., Kitabchi, A. E., Watson, K. E., & for the Diabetes Prevention Program Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2471 · Cited by 54
Diabetes Prevention Program (DPP) Research Group, Hamman, R. F., Horton, E., Barrett-Connor, E., Bray, G. A., Christophi, C. A., Crandall, J., Florez, J. C., Fowler, S., Goldberg, R., et al. (2015) · Diabetes · doi:10.2337/db14-0333 · Cited by 46
Reducing the Risk of Developing Diabetes
Ransom, T. P. P., Goldenberg, R., Mikalachki, A., Prebtani, A. P. H., & Punthakee, Z. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.013 · Cited by 43
Retnakaran, R. R., Qi, Y., Harris, S. B., Hanley, A. J., & Zinman, B. (2011) · Diabetes Care · doi:10.2337/dc11-0046 · Cited by 30
National evidence based guideline for the primary prevention of type 2 diabetes
Gómez, M. D. C., Walker, K. Z., & Buckley, A. (2009) · Cited by 20
Reducing the Risk of Developing Diabetes
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.004 · Cited by 4
Cited by
International exercise recommendations in older adults (ICFSR): Expert consensus guidelines
Izquierdo, M., Merchant, R. A., Morley, J. E., Anker, S. D., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bernabei, R., Cadore, E. L., Cesari, M., et al. (2021) · The Journal of nutrition, health and aging · doi:10.1007/s12603-021-1665-8 · Cited by 1,247
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Metadata
- Authors
- Aroda, V. R., & Ratner, R. E.
- Affiliations
- Brigham and Women's Hospital (US)
- Georgetown University (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Aroda, Vanita R.
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2018-11-01
- Volume
- 31
- Issue
- 4
- Pages
- 336-342
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC6243218
- OpenAlex
- W2901945957
- Cited by
- 70
- References
- 32
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 23 · 2023: 13 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 1
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes prevention, prediabetes, Diabetes Prevention Program, lifestyle intervention, obesity, gestational diabetes mellitus, microvascular complications, atherosclerosis, coronary artery calcium, long-term follow-up
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.